Genome British Columbia
14
2
4
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 14 trials
100.0%
+13.5% vs industry average
14%
2 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Mainstreaming Genetic Testing for Non-Ischemic Cardiomyopathy in Western Canada
Role: collaborator
National Active Surveillance Network and Pharmacogenomics of Adverse Drug Reactions in Children
Role: collaborator
Advancing Cardiac Care Unit-based Rapid Assessment and Treatment of hypErcholesterolemia
Role: collaborator
Integrating Pediatric Pharmacogenomic Testing Into the Canadian Health Care System
Role: collaborator
Epigenetic Health Benefits of Budesonide
Role: collaborator
PErsonalized Genomics for Prenatal Abnormalities Screening USing Maternal Blood
Role: collaborator
Field Randomization of Nerinetide (NA-1) Therapy in Early Responders
Role: collaborator
Chronic Obstructive Pulmonary Disease Biomarker Study
Role: collaborator
Real-world Clinical Effectiveness of Whole Genome and Transcriptome Analysis to Guide Advanced Cancer Care
Role: collaborator
Canadian COVID-19 Emergency Department Registry
Role: collaborator
Study of the Efficacy of New Non-invasive Prenatal Tests for Screening for Fetal Trisomies Using Maternal Blood
Role: collaborator
SpecTRA; A Study of the Validation of Protein Biomarkers in Transient Ischemic Attack
Role: collaborator
SpecTRA; An Observational Study of the Verification of Protein Biomarkers in Transient Ischemic Attack.
Role: collaborator
The Implementation of Pharmacogenomics Into Primary Care in British Columbia
Role: collaborator
All 14 trials loaded